Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge

 
• By Jessica Merrill

A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.

Business success concept with target as motivation (3D Rendering)
AstraZeneca's Farxiga was successful in chronic kidney disease • Source: Shutterstock

More from Genitourinary

More from Therapy Areas